Ernexa Therapeutics Inc. Receives Nasdaq Delisting Notice: Key Details for Investors
Ernexa Therapeutics Inc. (Nasdaq: ERNA; ERNAW) has filed a Form 8-K dated March 18, 2026, announcing a critical update regarding its listing status on The Nasdaq Stock Market LLC.
Key Points from the Report
- Nasdaq Delisting Notice: Ernexa Therapeutics Inc. has received a notice from Nasdaq stating that the company does not currently comply with the Minimum Bid Price Requirement for continued listing on the Nasdaq Capital Market.
- Extension Request and Hearing: Under Nasdaq Listing Rules, the company is eligible to request a hearing with the Nasdaq Hearings Panel. The Panel may grant an extension of up to 180 days from the date of the notice. Ernexa intends to present its plan to regain compliance with the Minimum Bid Price Requirement.
- Uncertainty Over Listing: There is no assurance that the Panel will grant a favorable decision or that Ernexa’s securities will remain listed on Nasdaq. The outcome of this process is uncertain and could have significant implications for shareholders.
- Forward-Looking Statements: The company’s statements regarding plans to request a hearing and compliance strategies are forward-looking and subject to risks and uncertainties. Actual results may differ materially from those expressed or implied.
Potentially Price-Sensitive Information for Shareholders
- Risk of Delisting: The potential delisting from Nasdaq is a material event that could significantly affect share value and liquidity. Investors should be aware that if the company is delisted, shares may trade on a less liquid over-the-counter market, which could impact trading volumes and share price.
- Compliance Plan: The company’s ability to retain its Nasdaq listing depends on successfully presenting and executing a remediation plan. Failure to do so could result in delisting.
- Uncertainty and Volatility: The report cautions investors not to place undue reliance on forward-looking statements. Volatility may increase as the outcome of the Nasdaq hearing process is unknown.
- Security Details: Ernexa’s common stock (par value \$0.005 per share, trading symbol ERNA) and common stock purchase warrants (trading symbol ERNAW) are both listed on Nasdaq, but their future listing status is in jeopardy due to this compliance issue.
Additional Details from the Filing
- Form 8-K Filing Date: March 18, 2026
- Exchange: The Nasdaq Stock Market LLC
- Emerging Growth Company Status: Ernexa has indicated it is not an emerging growth company.
- No Pre-commencement Tender Offer: The filing states that there is no pre-commencement tender offer or soliciting material associated with this event.
What Investors Should Watch For
- Panel Decision Timeline: The Nasdaq Hearings Panel has up to 180 days to render a decision. Investors should monitor further updates from Ernexa regarding the status of its compliance plan and any Panel decisions.
- Share Price Reaction: The threat of delisting is a significant event that could move share prices. If the company fails to regain compliance, or if investors perceive a high risk of delisting, share prices may decline sharply.
- Future Disclosures: Ernexa Therapeutics Inc. has committed to update shareholders only as required by law. Investors should remain vigilant for further filings and news releases.
Disclaimer
This article is based on the information contained in Ernexa Therapeutics Inc.’s Form 8-K filing dated March 18, 2026. The article includes forward-looking statements that are subject to risks and uncertainties. Actual outcomes may differ materially. Investors should perform their own due diligence and consult a financial advisor before making investment decisions. The author assumes no responsibility for investment actions taken based on this article.
View Ernexa Therapeutics Inc. Historical chart here
